Comparison · NCT00247273-992c8f87
5 mg Risedronate vs 150 mg Risedronate: Number of Participants With New Vertebral Fracture at Month 12, ITT Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 5 mg Risedronate vs 150 mg Risedronate: Number of Participants With New Vertebral Fracture at Month 12, ITT Population. Trial comparisons, record NCT00247273-992c8f87. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00247273-992c8f87
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0125 | 0.00633 | 0.0244 | wilson | |
| Risk in group 2 | 0.0123 | 0.00625 | 0.0241 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000153 | -0.0131 | 0.0135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.382 | 2.68 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.378 | 2.71 | log | |
| Number needed to treat, for one more participant with the outcome on 5 mg Risedronate than on 150 mg Risedronate | 6,520 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 5 mg Risedronate | 5 mg risedronate tablet, once daily for 2 years | 8 | 642 | OG000 |
| Group 2 | 150 mg Risedronate | 150 mg risedronate taken once a month for 2 years | 8 | 650 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With New Vertebral Fracture at Month 12, ITT Population
- Description
- At least 1 new fractured vertebra
- Time frame
- Baseline to Month 12
- Population
- ITT
Source ClinicalTrials.gov
Trial
- Title
- A Study of Monthly Risedronate for Osteoporosis
- NCT number
- NCT00247273
- Phases
- PHASE3
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- risedronate, risedronate
- Lead sponsor
- Warner Chilcott
- Results first posted
- 2011-06-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00247273?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00247273-992c8f87